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Accepted 10 July 2013Allogeneic blood or marrow transplantation is a unique
therapeutic modality merging cytoreductive treatment and
immunotherapy mediated by alloreactive donor T cells and/
or natural killer (NK) cells. The potential potency of this
graft-versus-malignancy (GVM) reaction and recognition
that conditioning-induced organ toxicity and inﬂammation
may promote the development of graft-versus-host disease
(GVHD) have led to the development of reduced-intensity
conditioning (RIC) regimens. The goal of these “mini-trans-
plants” is to achieve donor cell engraftment and develop-
ment of GVM with less treatment-associated toxicities and
GVHD. Following the ﬁrst clinical reports describing these
less toxic conditioning regimens [1], a broad spectrum of
regimens has been developed, ranging from truly non-
myeloablative, purely immunosuppressive regimens to fairly
aggressive regimens leading to signiﬁcant transient myelo-
suppression. An operational deﬁnition of RIC was formulated
to contain< 500 cGy of total body irradiation (TBI) as a single
fraction or <800 cGy if fractionated, <9 mg/kg busulfan oral
(or intravenous equivalent), <140 mg/m2 melphalan, or
<10 mg/kg thiotepa [2]. The introduction of these novel
conditioning regimens within the last 15 years has allowed
signiﬁcant expansion of the age limits of allogeneic blood or
marrow transplantation recipients. The Center for Interna-
tional Blood and Marrow Transplant Research registry data
demonstrate that the number of RIC transplants has steadily
increased over the last decade, indicating that RIC trans-
plants have become standard of care.
However, how much conditioning intensity is needed to
achieve engraftment and adequate reduction of tumor load
and to prepare the platform for the GVM effect remains an
unresolved question. In particular, the question comparing
myeloablative therapy with RIC remains to be settled.
Furthermore, given the abundance of different RIC regimens
and the paucity of controlled randomized trials, it is a huge
challenge to interpret the results of various studies using
these different RIC regimens and to determine which
regimen is most suitable for a given patient.Financial disclosure: See Acknowledgments on page 1276.
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http://dx.doi.org/10.1016/j.bbmt.2013.07.011Results from 2 randomized controlled studies may now
help to shed some light on this conundrum and provide
some answers. The investigators of both studies should be
applauded for conducting these trials and helping to provide
evidence-based insights into the effects of different dose
intensities. Among the various RIC regimens, the Slavin
protocol (ﬂudarabine, busulfan, and antithymocyte globulin
[Flu-Bu-ATG]) [3] and the “Seattle” protocol (ﬂudarabine/
2 Gy TBI [Flu-TBI] followed by mycophenolate mofetil and
cyclosporine immunosuppression) [4] have become quite
popular and are the regimens assessed in these trials.
In this issue of Biologyof Blood andMarrowTransplantation,
Kornblit et al. [5] from the Seattle group report the results of
a randomized trial comparing 2 Gy TBI alone with Flu-TBI
(ﬂudarabine 90 mg/m2). Although interpretation of the
study is somewhat affected by slow accrual and the small
sample size, the study did generate some intriguing results
suggesting that TBI-only is inferior to Flu-TBI, becausepatients
in the TBI-only group had (1) signiﬁcantly lower donor T and
NK cell chimerism; (2) a trend for higher incidences of
progression/relapse, relapse-related mortality, and lower
overall survival; and (3) a lower progression-free survival.
Interestingly, there were no differences in GVHD, nonrelapse
mortality, and infection rates between the groups. These
results suggest that the addition of ﬂudarabine to 2 Gy TBI
resulted in improveddiseasecontrol anda trend towardbetter
overall survival, which may be partially attributed to direct
antimalignancy effects of ﬂudarabine and/or the higher donor
T cell and NK cell chimerism leading to better GVM effects.
Earlier this year, Blaise and coworkers [6] published the
results of a randomized trial comparing the Flu-TBI Seattle
protocol and the Flu-Bu-ATG Slavin protocol. Interestingly,
therewas no signiﬁcant difference in overall survival between
the two regimens. However, the more intense Flu-Bu-ATG
regimen provided signiﬁcantly better disease control, which
was off-set by a higher incidence of acute GVHD grades II to IV
(despite the use of thymoglobulin, although at a lowdose) and
nonrelapsemortality. Furthermore, the Flu-Bu-ATG recipients
appeared to have a lower quality of life.
What are the conclusions from these trials? Both studies
conﬁrm the notion that long-term survival can be achieved
with RIC but also that dose does matter and may be of
particular relevance in patients with high risk and active
disease at the time of transplant. However, the sobering
reality is that despite better disease control, higher dose
intensity still does not translate into improved overall
survival. These results clearly underscore the necessity to
further improve the outcome after RIC by reducing disease
recurrence and nonrelapse mortality. Therefore, using these
RIC regimens as a starting point, it is our hope that in
addition to ﬁne tuning the current regimen (eg, optimal dose
M.R. Grunwald / Biol Blood Marrow Transplant 19 (2013) 1275e12781276of thymoglobulin), novel emerging molecular targeting
approaches to separate GVHD and GVM (eg, HDAC inhibitors
[7], proteasome inhibitors [8], JAK/STAT inhibitors [9,10], and
demethylating agents [11]) can be validated clinically.
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Accepted 9 July 2013Acute myelogenous leukemia (AML) and myelodysplastic
syndrome (MDS) are diseases that affect predominantly
older adults, and it is precisely this group of patients that
continues to suffer from particularly poor outcomes [1-4].
Although hematopoietic cell transplantation (HCT) has
emerged as an important treatment strategy for patients
with high-risk hematologic malignancies, as recently as 2
decades ago this modality was limited mainly to patients
under age 50 [5]. This arbitrary age restriction was related
primarily to concerns about early nonrelapse mortality
(NRM) and morbidity. Initial studies of HCT using myeloa-
blative conditioning regimens suggested that patients over
age 50 may experience increased toxicity from chemo-
therapy, as well as higher rates of graft-versus-host disease
(GVHD) [6]. Several factors, including improved supportive
care and the development of a decrease in intensity condi-
tioning (RIC) regimens, have led to reduced mortality after
allogeneic HCT [7]. This progress, along with the lack of
effective alternative treatment strategies for many patients,has rekindled interest in HCT for older adults with hemato-
logic malignancies and has led to an increase in the use of
HCT in these individuals [5,8-11].
Although little is known about quality of life after RIC HCT
in older patients [12], recent studies have reported some-
what promising survival results. A large database analysis of
patients age >40 undergoing RIC-HCT for AML or MDS
uncovered no adverse effect of age on NRM, disease-free
survival, or overall survival (OS) [8]. In addition, a recent
study of patients ages 60 to 70 with high-risk MDS or
secondary AML receiving RIC-HCT versus azacitidine therapy
also revealed fairly encouraging outcomes for the HCT group,
with a 2-year OS of 39%, NRM of 33%, and relapse rate of 30%
[10]. Although RIC-HCT has become an accepted strategy for
treating patients age >50, this approach is currently used in
only a relatively small proportion of older adults with AML
and MDS [13]. Moreover, while an increasing number of
studies have focused on patients age >60, few studies have
focused on patients age >70 [14].
In this issue of Biology of Blood and Marrow Trans-
plantation, Brunner et al [15] report a retrospective analysis
of 54 patients age >70 undergoing HCT at 2 afﬁliated insti-
tutions [15]. The patients had a heterogeneous group of
diseases, but more than two-thirds had AML or MDS. All
patients received an RIC regimen, mostly busuﬂan and ﬂu-
darabine, and most patients received their grafts from
matched unrelated donors. Two-year OS and progression-
free survival in the entire population were both 39%, with
reasonable rates of GVHD. Two-year OS was 53% in patients
with AML or MDS with favorable or intermediate-risk cyto-
genetics (only 1 patient had favorable cytogenetics),
compared with 30% in those with adverse cytogenetics or
